Roxane Laboratories, Inc. Announces the Launch of Levetiracetam Tablets and Oral Solution

COLUMBUS, Ohio, Jan. 15 /PRNewswire/ — Roxane Laboratories, Inc.
announced today the approval of their Abbreviated New Drug Application (ANDA)
for Levetiracetam Tablets, 250mg, 500mg, 750mg, 1000mg, and Oral Solution
100mg/mL. The product is available for immediate shipment to wholesalers and
pharmacies nationwide.

Roxane Laboratories’ Levetiracetam Tablets and Oral Solution are AB rated
to UCB, Inc.’s KEPPRA(R) (levetiracetam). Annual sales of KEPPRA(R) Tablets
and Oral Solution are approximately $1.28 Billion (1).

Full prescribing information for Levetiracetam Tablets and Oral Solution
is available on the Roxane Laboratories website at www.Roxane.com or upon
request by calling Roxane Laboratories Technical Product Information at
1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square
foot manufacturing and laboratory facility. The facility spans 70 acres and
currently employs over 1,000 people. Currently, Roxane Laboratories
markets over 75 medications in nearly 250 package sizes, focusing on an
expanding line of Multisource pharmaceutical products including: bulk and
unit-dose liquids and solids; coated, sustained-release and controlled-release
tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim
Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim
group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US
headquarters to seven subsidiaries and a member of the Boehringer Ingelheim
group of companies.

The Boehringer Ingelheim group is one of the world’s 20 leading
pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates
globally with 135 affiliates in 47 countries and approximately 39,800
employees. Since it was founded in 1885, the family-owned company has been
committed to researching, developing, manufacturing and marketing novel
products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9
billion euro) while spending approximately one-fifth of net sales in its
largest business segment, Prescription Medicines, on research and development.

For more information on Boehringer Ingelheim, please visit
http://us.boehringer-ingelheim.com.

    (1) IMS MAT dollar sales ending 10/2008

    KEPPRA(R) is a registered trademark of UCB, Inc.

    Editorial Contact for Roxane Laboratories:
    Angela Chirico, 614.272.4774
    Angela.Chirico@boehringer-ingelheim.com

SOURCE Roxane Laboratories, Inc.